Elevation Oncology Accepts a Buyout Offer from Concentra Biosciences

Published on 09/06/2025 at 23:05

S&P Capital IQ

-0.59%

On June 9, 2025, Elevation Oncology Inc announced that it has accepted a buyout offer from Concentra Biosciences, Concentra will pay 36 cents per share, slightly above Company's recent closing price of 32 cents, and Company?s stockholders will receive a contingent value right for proceeds from the sale of the biotech's HER3-targeted ADC, EO-1022, and any leftover cash above $26.4 million.

Latest news about Elevation Oncology, Inc.

Elevation Oncology, Inc. Enters into Mutual Release and Termination Agreement with CSPC Megalith Biopharmaceutical Co., Ltd	03/07	CI
Elevation Oncology, Inc.(NasdaqCM:ELEV) dropped from S&P Global BMI Index	23/06	CI
TD Cowen Downgrades Elevation Oncology to Hold From Buy	10/06	MT
CORRECTION : HC Wainwright Downgrades Elevation Oncology to Neutral From Buy	10/06	MT
HC Wainwright Downgrades Elevation Oncology to Neutral From Buy	10/06	MT
Elevation Oncology Accepts a Buyout Offer from Concentra Biosciences	09/06	CI
Concentra Biosciences, LLC entered into a definitive merger agreement to acquire Elevation Oncology, Inc. for $21.4 million.	09/06	CI
Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR	09/06	RE
Elevation Oncology, Inc. Announces Management Changes, Effective as of June 30, 2025	09/06	CI
Elevation Oncology, Inc. Announces Chief Executive Officer Changes, Effective June 30, 2025	09/06	CI
Elevation Oncology Explores Strategic Alternatives	15/05	CI
Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05	CI
Elevation Oncology, Inc. Voluntarily Prepays $32.3 Million Term Loan	06/05	CI
Elevation Oncology Presents Preclinical Proof-Of-Concept Data for EO-1022 At the American Association for Cancer Research Annual Meeting 2025	25/04	CI
BML Capital Management Sends a Letter to the Board of Elevation Oncology	16/04	CI
Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing	05/04	RE
Stephens Downgrades Elevation Oncology to Equal Weight From Overweight, Adjusts Price Target to $1 From $5	24/03	MT
Wedbush Downgrades Elevation Oncology to Neutral From Outperform, Cuts Price Target to $1.60 From $5	21/03	MT
Leerink Downgrades Elevation Oncology to Market Perform From Outperform, Adjusts Price Target to $1 From $9	21/03	MT
Piper Sandler Downgrades Elevation Oncology to Neutral From Overweight, Adjusts Price Target to $0.70 From $10	21/03	MT
Sector Update: Health Care Stocks Decline Pre-Bell Thursday	20/03	MT
Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell	20/03	MT
Elevation Oncology, Inc. to Discontinue Development of EO-3021	20/03	CI
Elevation Oncology, Inc. Announces Step Down of Valerie M. Jansen as Chief Medical Officer, Effective March 31, 2025	20/03	CI
Elevation Oncology, Inc. Implements A Workforce Reduction of Approximately 70%	20/03	CI